These findings raise the possibility of exploiting NLRC5-SA for cancer gene therapy using viral vectors such adeno-associated or oncolytic viruses to restore MHC-I expression and antitumor immunity in MHC-I-defective tumors that are unresponsive to ICB therapy. The gene discussed is NLRC5; the disease is cancer.